BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24021671)

  • 21. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
    Lillico R; Lawrence CK; Lakowski TM
    J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MLL is essential for NUP98-HOXA9-induced leukemia.
    Shima Y; Yumoto M; Katsumoto T; Kitabayashi I
    Leukemia; 2017 Oct; 31(10):2200-2210. PubMed ID: 28210005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
    Arai S; Yoshimi A; Shimabe M; Ichikawa M; Nakagawa M; Imai Y; Goyama S; Kurokawa M
    Blood; 2011 Jun; 117(23):6304-14. PubMed ID: 21190993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
    Monroe SC; Jo SY; Sanders DS; Basrur V; Elenitoba-Johnson KS; Slany RK; Hess JL
    Exp Hematol; 2011 Jan; 39(1):77-86.e1-5. PubMed ID: 20854876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape.
    Chiarella E; Aloisio A; Scicchitano S; Todoerti K; Cosentino EG; Lico D; Neri A; Amodio N; Bond HM; Mesuraca M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.
    Biswas D; Milne TA; Basrur V; Kim J; Elenitoba-Johnson KS; Allis CD; Roeder RG
    Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15751-6. PubMed ID: 21896721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The YEATS domain epigenetic reader proteins ENL and AF9 and their therapeutic value in leukemia.
    Hu H; Muntean AG
    Exp Hematol; 2023 Aug; 124():15-21. PubMed ID: 37295550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation and characterization of bioluminescent xenograft mouse models of MLL-related acute leukemias and in vivo evaluation of luciferase-targeting siRNA nanoparticles.
    Fazzina R; Lombardini L; Mezzanotte L; Roda A; Hrelia P; Pession A; Tonelli R
    Int J Oncol; 2012 Aug; 41(2):621-8. PubMed ID: 22665135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
    Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
    Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
    Wang QF; Wu G; Mi S; He F; Wu J; Dong J; Luo RT; Mattison R; Kaberlein JJ; Prabhakar S; Ji H; Thirman MJ
    Blood; 2011 Jun; 117(25):6895-905. PubMed ID: 21518926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.
    Thiel AT; Blessington P; Zou T; Feather D; Wu X; Yan J; Zhang H; Liu Z; Ernst P; Koretzky GA; Hua X
    Cancer Cell; 2010 Feb; 17(2):148-59. PubMed ID: 20159607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence.
    Lu B; Klingbeil O; Tarumoto Y; Somerville TDD; Huang YH; Wei Y; Wai DC; Low JKK; Milazzo JP; Wu XS; Cao Z; Yan X; Demerdash OE; Huang G; Mackay JP; Kinney JB; Shi J; Vakoc CR
    Cancer Cell; 2018 Dec; 34(6):970-981.e8. PubMed ID: 30503706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.
    Murai MJ; Pollock J; He S; Miao H; Purohit T; Yokom A; Hess JL; Muntean AG; Grembecka J; Cierpicki T
    Blood; 2014 Dec; 124(25):3730-7. PubMed ID: 25305204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
    Chu Y; Chen Y; Guo H; Li M; Wang B; Shi D; Cheng X; Guan J; Wang X; Xue C; Cheng T; Shi J; Yuan W
    Oncogene; 2020 Dec; 39(50):7239-7252. PubMed ID: 33037410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
    Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
    Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
    Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
    Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
    Ropa J; Saha N; Hu H; Peterson LF; Talpaz M; Muntean AG
    Haematologica; 2020 Sep; 105(9):2273-2285. PubMed ID: 33054052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
    Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.
    Zhou J; Wu J; Li B; Liu D; Yu J; Yan X; Zheng S; Wang J; Zhang L; Zhang L; He F; Li Q; Chen A; Zhang Y; Zhao X; Guan Y; Zhao X; Yan J; Ni J; Nobrega MA; Löwenberg B; Delwel R; Valk PJ; Kumar A; Xie L; Tenen DG; Huang G; Wang QF
    Leukemia; 2014 Jul; 28(7):1436-48. PubMed ID: 24445817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
    Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
    Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.